Advanced search
Publication Cover
OncoTargets and Therapy Volume 15, 2022 - Issue
Submit an article Journal homepage
139
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Association Mining Identifies MAL2 as a Novel Tumor Suppressor in Colorectal Cancer

Kailai Wang1 Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, People’s Republic of ChinaView further author information
,
Yanmei Yang2 Key Laboratory of Reproductive and Genetics, Ministry of Education, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310006, People’s Republic of ChinaView further author information
,
Shu Zheng1 Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-2521-190XView further author information
ORCID Icon &
Wangxiong Hu1 Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
Pages 761-769 | Published online: 09 Jul 2022

References

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
  • Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
  • Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193. doi:10.3322/caac.21395
  • Murphy CC, Harlan LC, Lund JL, Lynch CF, Geiger AM. Patterns of colorectal cancer care in the United States: 1990–2010. J Natl Cancer Inst. 2015;107(10). doi:10.1093/jnci/djv198
  • Martinez-Jimenez F, Muinos F, Sentis I, et al. A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020;20(10):555–572. doi:10.1038/s41568-020-0290-x
  • Uttayamakul S, Oudot-Mellakh T, Nakayama EE, et al. Genome-wide association study of HIV-related lipoatrophy in Thai patients: association of a DLGAP1 polymorphism with fat loss. AIDS Res Hum Retroviruses. 2015;31(8):792–796. doi:10.1089/aid.2014.0266
  • Wang L, Feng Z, Zhang X, Zhang X, Zhang X. DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics. 2010;26(1):136–138. doi:10.1093/bioinformatics/btp612
  • Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9:559. doi:10.1186/1471-2105-9-559
  • Hu W, Yang Y, Li X, et al. Multi-omics approach reveals distinct differences in left- and right-sided colon cancer. Mol Cancer Res. 2018;16(3):476–485. doi:10.1158/1541-7786.MCR-17-0483
  • Li X, Hu W, Zhou J, et al. CLCA1 suppresses colorectal cancer aggressiveness via inhibition of the Wnt/beta-catenin signaling pathway. Cell Commun Signal. 2017;15(1):38. doi:10.1186/s12964-017-0192-z
  • de Marco MC, Martin-Belmonte F, Kremer L, et al. MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells. J Cell Biol. 2002;159(1):37–44. doi:10.1083/jcb.200206033
  • Marazuela M, Acevedo A, Garcia-Lopez MA, Adrados M, de Marco MC, Alonso MA. Expression of MAL2, an integral protein component of the machinery for basolateral-to-apical transcytosis, in human epithelia. J Histochem Cytochem. 2004;52(2):243–252. doi:10.1177/002215540405200212
  • In JG, Striz AC, Bernad A, Tuma PL. Serine/threonine kinase 16 and MAL2 regulate constitutive secretion of soluble cargo in hepatic cells. Biochem J. 2014;463(2):201–213. doi:10.1042/BJ20140468
  • In JG, Tuma PL. MAL2 selectively regulates polymeric IgA receptor delivery from the Golgi to the plasma membrane in WIF-B cells. Traffic. 2010;11(8):1056–1066. doi:10.1111/j.1600-0854.2010.01074.x
  • Eguchi D, Ohuchida K, Kozono S, et al. MAL2 expression predicts distant metastasis and short survival in pancreatic cancer. Surgery. 2013;154(3):573–582. doi:10.1016/j.surg.2013.03.010
  • Byrne JA, Maleki S, Hardy JR, et al. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer. 2010;10:497. doi:10.1186/1471-2407-10-497
  • Bhandari A, Shen Y, Sindan N, et al. MAL2 promotes proliferation, migration, and invasion through regulating epithelial-mesenchymal transition in breast cancer cell lines. Biochem Biophys Res Commun. 2018;504(2):434–439. doi:10.1016/j.bbrc.2018.08.187
  • Fang Y, Wang L, Wan C, et al. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. J Clin Invest. 2021;131(1). doi:10.1172/JCI140837
  • Lopez-Coral A, Del Vecchio GJ, Chahine JJ, Kallakury BV, Tuma PL. MAL2-induced actin-based protrusion formation is anti-oncogenic in hepatocellular carcinoma. Cancers (Basel). 2020;12(2):422. doi:10.3390/cancers12020422
  • Baggiolini A, Callahan SJ, Trieu T, et al. Developmental chromatin programs determine oncogenic competence in melanoma. Science. 2021;373(6559). doi:10.1126/science.abc1048

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.